

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

November 20, 2024

Company: Chordia Therapeutics, Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: Chief Financial Officer Kentaro Kume

Announcement of International Nonproprietary Name (INN)
for CTX-712

Kanagawa Japan

November 20, 2024 – Chordia Therapeutics K.K. (Head Office: Fujisawa City, Kanagawa Prefecture; Chief Executive Officer : Hiroshi Miyake) announced that the World Health Organization (WHO) has released the following International Nonproprietary Name (INN) for our CLK inhibitor CTX-712 as a recommended INN (rINN).

Development Code	International Nonproprietary Name (INN)
CTX-712	rogocekib

An International Nonproprietary Name (INN) is the proper name for a medicinal substance that is common worldwide and is discussed and named by the World Health Organization (WHO). Since multiple pharmaceutical products contain a single compound, giving a single standard name to a substance is the best way to facilitate communication regarding pharmaceutical drugs. Therefore, we are confident that our acquisition of the International Nonproprietary Name (INN) is a good step forward in our activities toward commercialization. We will use the generic name instead of the Development Code for the above development items.

About CLK inhibitor rogocekib (Development code : CTX-712)

Rogokekib is a first-in-class, selective, oral, small molecule inhibitor of CDC2-like kinase (CLK), a key regulator of the RNA splicing response that plays an important role in cell proliferation.

We are currently conducting Phase 1/2 clinical trials in the U.S. For details of the U.S. Phase 1/2 clinical trial, please visit clinicaltrials.gov/ (NCT05732103).

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia's lead asset, CLK inhibitor CTX-712, is under Phase 1/2 clinical study in the US. CTX-712 potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.